Association study of the SCN1 gene polymorphism and effective dose of lamotrigine

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 109, Issue 10, 2009, Pages 57-62

  Krikova, E V ^a   Valdman, E A ^a   Avakyan, G N ^a   Andreev, Y A A ^a   Denisov, E V ^a   Rider, F K ^a   Biktimerov, R R ^a   Chukanova, A S ^a   Burd, S G ^a  

^a NONE

Author keywords

Epilepsy; Gene polymorphism; Lamotrigine; SCN1 gene

Indexed keywords

LAMOTRIGINE;

ALLELE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; EPILEPSY; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PATHOGENESIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; SCN1 GENE;

EID: 77949448455     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Abe T., Seo T., Ishitsu T. Et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol 2008; 66: 2: 304-307.
2. Aronica E., Yankaya B., Troost D. Et al. Induction of neonatal sodium channel II and III alpha-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus. Eur J Neurosci 2001; 13: 6: 1261-1266.
3. Beck H. Plasticity of antiepileptic drug targets. Epilepsia 2007; 48: Suppl 1: 14-18.
4. Brodie M.J., Richens A., Yuen A.W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Car- bamazepine 1995.
5. Everett K.V., Chioza B., Aicardi J. Et al. Linkage and association analysis of CACNG3 in childhood absence epilepsy. Eur J Hum Genet 2007; 15: 4: 463-472.
6. Harkin L.A., McMahon J.M., Iona X. Et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 2007; 130: Pt 3: 843-852.
7. Heinzen E.L., Yoon W., Tate S.K. Et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet 2007; 80: 5: 876-883.
8. Kanai K., Hirose S., Oguni H. Et al. Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity. Neurology 2004; 63: 2: 329-334.
9. Miller A.A., Wheatley P., Sawyer D.A. Et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 1986; 27: 5: 483-489.
10. Sabers A., Buchholt J.M., Uldall P., Hansen E.L. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 1-2: 151-154.
11. Sabers A., Ohman I., Christensen J., Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 4: 570-571.
12. Steiner T.J., Dellaportas C.I., Findley L.J. Et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 5: 601-607.
13. Tate S.K., Depondt C., Sisodiya S.M. Et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 15: 5507-5512.
14. Urak L., Feucht M., Fathi N. Et al. A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity. Hum Mol Genet 2006; 15: 16: 2533-2541.
15. Xie X., Lancaster B., Peakman T., Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflugers Arch 1995; 430: 3: 437-446.
16. Yang Y.C., Kuo C.C. Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. Mol Pharmacol 2002; 62: 5: 1228-1237.
17. Yang Y.C., Kuo C.C. An inactivation stabilizer of the Na+ channel acts as an opportunistic pore blocker modulated by external Na+. J Gen Physiol 2005; 125: 5: 465-481.